Androgen therapy may slow progress of Alzheimer's diseaseDecember 20, 2006Experiments on mouse models of Alzheimer's disease (AD) suggest that treatment with male sex hormones might slow its progression. The findings, published in the December 20 issue of The Journal of Neuroscience, provide new insight into the relationship between testosterone loss and AD, which affects 4.5 million Americans. Senior author Christian Pike, PhD, of the University of Southern California (USC), with colleagues at USC and the University of California, Irvine, sought to better understand the role hormones play in aging and disease. Recent studies had already established a link between testosterone loss in men and AD due to natural aging. The research team established a correlation between low testosterone and elevated beta-amyloid (Aâ), a protein that accumulates abnormally in AD patients. This finding, they say, suggests that testosterone depletion in aging men may be a risk factor for AD by promoting accumulation of Aâ in the brain. Testosterone, the primary male sex hormone, is one in a group of related steroid hormones referred to as androgens. Recent studies suggest that androgens may lower Aâ levels.
"This study raises the possibility that androgen replacement therapy might lower the risk for Alzheimer's, but this is far from proven," says Sam Gandy, MD, PhD, chair of the Alzheimer's Association's Medical and Scientific Advisory Council and director of the Farber Institute for Neurosciences at Thomas Jefferson University. "Because testosterone is rapidly converted to estrogen after entry into neurons, the new data are logical, and they dovetail well with historical data." Using a mouse model of AD, in which three genes had been altered, researchers evaluated how experimental manipulation of sex hormones affected the progress of the disease. Researchers removed the testes of young adult male mice and over several months, treated some with a testosterone hormone and others with a placebo. After the treatment period, memory-related behavior and measures of Alzheimer-like pathology were measured in the different groups of mice. The castrated models that received the placebo showed poor working memory and high brain levels of Aâ. However, both Aâ accumulation and cognitive decline were prevented in mice treated with the hormone therapy. "Although the results of the study predict that androgen therapy has the potential to reduce the risk of AD in at least some men," Pike said, "clinical studies will be required to determine when and how to use androgen therapy." Society for Neuroscience | |||||||||||||||||||||
|
Related Testosterone News Articles Why a common treatment for prostate cancer ultimately fails Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences. Testosterone key to disease transmission High levels of testosterone may be a key factor in spreading disease among mice, according to biologists. The findings could help explain why males in a population are often more likely to get infected, and transmit disease. Prostate cancer patients undergoing hormone therapy may experience cognitive effects A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients-- such as in the ability to recall and concentrate. New study points to agriculture in frog sexual abnormalities A farm irrigation canal would seem a healthier place for toads than a ditch by a supermarket parking lot. Pregnancy may help protect against bladder cancer Pregnancy seems to confer some protection against bladder cancer in mice, scientists have found. Zebrafish enable scientists to study the migration of neurons that enable sexual maturity Scientists are watching a small group of neurons that enable sexual maturity and fertility make a critical journey: from where they form, near the developing nose, to deep inside the brain. How advanced prostate cancer becomes resistant to androgen-deprivation therapy For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. Many men with low testosterone levels do not receive treatment The majority of men with androgen deficiency may not be receiving treatment despite having sufficient access to care, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Disabling mouse enzyme increases fertility Changing the sugars attached to a hormone produced in the pituitary gland increased fertility levels in mice nearly 50 percent, a research group at Washington University School of Medicine in St. Louis has found. Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians Genetic differences may explain the greater risk for prostate cancer among Caucasian men compared with Hispanic men, which could help clinicians predict who is more likely to develop the disease. More Testosterone News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||